Physician profile
Timothy Daugherty
NPI 1821031840
$7,953.46
in general payments reported to CMS, 2019-2025
46 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $662 · 2021: $1,324 · 2022: $1,379 · 2023: $1,646 · 2024: $1,133 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,709.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,429.31 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $981.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $720.47 | 2019-2025 | |
| Amgen INC. | $709.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $424.16 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $340.29 | 2020-2025 | Spravato |
| Pfizer INC. | $316.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $275.70 | 2019-2025 | Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $247.47 | 2020-2024 | Nexletol |
| Glaxosmithkline, LLC. | $191.57 | 2021-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $148.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $145.56 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $143.98 | 2019-2024 | Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.25 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.76 | 2019-2024 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.